Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease

IMPORTANCE: The EMERGE and ENGAGE phase 3 randomized clinical trials of aducanumab provide a robust data set to characterize amyloid-related imaging abnormalities (ARIA) that occur with treatment with aducanumab, an amyloid-β (Aβ)–targeting monoclonal antibody, in patients with mild cognitive impair...

Descripción completa

Detalles Bibliográficos
Autores principales: Salloway, Stephen, Chalkias, Spyros, Barkhof, Frederik, Burkett, Patrick, Barakos, Jerome, Purcell, Derk, Suhy, Joyce, Forrestal, Fiona, Tian, Ying, Umans, Kimberly, Wang, Guanfang, Singhal, Priya, Budd Haeberlein, Samantha, Smirnakis, Karen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609465/
https://www.ncbi.nlm.nih.gov/pubmed/34807243
http://dx.doi.org/10.1001/jamaneurol.2021.4161

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609465/
https://www.ncbi.nlm.nih.gov/pubmed/34807243
http://dx.doi.org/10.1001/jamaneurol.2021.4161

Ejemplares similares